Bei Akademie registrieren
Gilead Sciences, US3755581036

Gilead Sciences stock pre-market at EUR 139.78: biotech group slightly higher

Published on 10/19/2026 at 08:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences develops and sells medicines in virology, oncology and inflammation. At Lang & Schwarz the stock trades pre-market at EUR 139.78 on October 19, 2026, 0.68 percent above the Xetra close of October 16, 2026.

Business model and market context

  • Gilead Sciences develops and sells medicines across virology, oncology and inflammation.
  • The company’s home market is the Nasdaq in the United States on October 19, 2026.
  • Gilead Sciences stock trades pre-market at EUR 139.78 at 8:16 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.68 percent above the Xetra close of October 16, 2026.
NASDAQ Handelssaal mit Biotech-Charts und Tradern für Gilead Sciences Aktie US3755581036
Gilead Sciences NASDAQ Handelssaal ISIN US3755581036 Biotech-Sektor grüne Kerzencharts Trader digitale Bildschirme, Illustration mit AI erstellt.

Gilead Sciences develops and sells medicines in virology, oncology and inflammation, according to its corporate website. Gilead Sciences stock trades pre-market at EUR 139.78 at 8:16 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.68 percent above the Xetra close of October 16, 2026 (EUR 138.84).

Ahead of the Xetra open

The move amounts to plus EUR 0.94 versus the Xetra close. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.

Business and market context

The company website describes a pipeline spanning virology, oncology and inflammation. The home market is the Nasdaq in the United States on October 19, 2026. Market context: Market report Nasdaq Composite.

More news and analysis on Gilead Sciences stock

Disclaimer...
en | US3755581036 | GILEAD SCIENCES | boerse | 70358405 | bgmi